Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2023-03-03
4:30 pm
Sale
13DMarker Therapeutics, Inc.
MRKR
Aisling Capital IV LP464,285
5.46%
-3,035,715decrease
(-86.73%)
View
2023-02-08
5:00 pm
Purchase
13GElevation Oncology, Inc.
ELEV
Aisling Capital IV LP2,876,561
12.34%
10,413increase
(+0.36%)
View
2022-02-14
12:16 pm
Purchase
13GElevation Oncology, Inc.
ELEV
Aisling Capital IV LP2,866,148
12.33%
2,866,148increase
(New Position)
View
2022-02-14
12:14 pm
Sale
13GViracta Therapeutics, Inc.
VIRX
Aisling Capital IV LP288,571
0.77%
-9,811,429decrease
(-97.14%)
View
2019-07-15
4:15 pm
Purchase
13GSUNESIS PHARMACEUTICALS INC
SNSS
Aisling Capital IV LP10,100,000
10%
2,500,000increase
(+32.89%)
View
2019-02-05
4:06 pm
Sale
13GProtagonist Therapeutics, Inc.
PTGX
Aisling Capital IV LP0
0%
-1,015,761decrease
(Position Closed)
View
2019-01-24
5:21 pm
Purchase
13GSUNESIS PHARMACEUTICALS INC
SNSS
Aisling Capital IV LP7,600,000
12.6%
4,625,000increase
(+155.46%)
View
2018-10-19
5:09 pm
Purchase
13DMarker Therapeutics, Inc.
MRKR
Aisling Capital IV LP3,500,000
7.7%
3,500,000increase
(New Position)
View